ERBB2 and gastric cancer: In contrast, there was no significant difference in the OS of the HER2-negative gastric cancer patients with both p-Smad2 and c-Met expression (n = 79) and the patients with p-Smad2-negative and/or c-Met-negative expression (n = 382) (p = 0.478) (Fig. 5B).